2021

• Lee, Z., Llanes, E., Sukmawan, R., Thongtang, N., Ho, H., Barter, P. (2021). Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region. Lipids in Health and Disease, 20(1), 33. [More Information]
• Januszewski, A., Chen, D., Scott, R., O'Connell, R., Aryal, N., Sullivan, D., Watts, G., Taskinen, M., Barter, P., Best, J., Simes, R., Keech, A., Jenkins, A. (2021). Relationship of low molecular weight fluorophore levels with clinical factors and fenofibrate effects in adults with type 2 diabetes. Scientific Reports, 11(1), 18708. [More Information]

2020

• Tucker, B., McClelland, R., Allison, M., Budoff, M., Wu, B., Barter, P., Rye, K., Ong, K. (2020). Relationship of fibroblast growth factor 21 levels with inflammation, lipoproteins and non-alcoholic fatty liver disease. Atherosclerosis, 299, 38-44. [More Information]

2019

• Hui, N., Barter, P., Ong, K., Rye, K. (2019). Altered HDL metabolism in metabolic disorders: Insights into the therapeutic potential of HDL. Clinical Science, 133(21), 2221-2235. [More Information]
• Wu, B., Sun, Y., Ong, K., Li, Y., Tang, S., Barter, P., Rye, K. (2019). Apolipoprotein A-I Protects Against Pregnancy-Induced Insulin Resistance in Rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 39(6), 1160-1171. [More Information]
• Hou, L., Tang, S., Wu, B., Ong, K., Westerterp, M., Barter, P., Cochran, B., Tabet, F., Rye, K. (2019). Apolipoprotein A-l improves pancreatic β-cell function independent of the ATP-binding cassette transporters ABCA1 and ABCG1. The FASEB Journal, 33(7), 8479-8489. [More Information]
• Ong, K., McClelland, R., Allison, M., Kokkinos, J., Wu, B., Rye, K., Barter, P. (2019). Association of elevated circulating fibroblast growth factor 21 levels with prevalent and incident metabolic syndrome: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 281, 200-206. [More Information]
• Palmer, M., Barter, P., Lundmand, P., Nicholls, S., Toth, P., Karlson, B. (2019). Comparing a novel equation for calculating low-density lipoprotein cholesterol with th3e Friedewald equation: A VOYAGER analysis. Clinical Biochemistry, 64, 24-29. [More Information]
• Ong, K., Hui, N., Januszewski, A., Kaakoush, N., Xu, A., Fayyad, R., DeMicco, D., Jenkins, A., Keech, A., Waters, D., et al (2019). High plasma FGF21 levels predicts major cardiovascular events in patients treated with atorvastatin (from the treating to new targets [TNT] study). Metabolism: Clinical and Experimental, 93, 93-99. [More Information]
• Wu, B., Li, Y., Ong, K., Sun, Y., Johns, D., Barter, P., Rye, K. (2019). The Cholesteryl Ester Transfer Protein Inhibitor, des-Fluoro-Anacetrapib, Prevents Vein Bypass-induced Neointimal Hyperplasia in New Zealand White Rabbits. Scientific Reports, 9(1). [More Information]
• Magdas, A., Ding, J., McClelland, R., Allison, M., Barter, P., Rye, K., Ong, K. (2019). The relationship of circulating fibroblast growth factor 21 levels with pericardial fat: The Multi-Ethnic Study of Atherosclerosis. Scientific Reports, 9(1). [More Information]

2018

• Nicholls, S., Lincoff, A., Bash, D., Ballantyne, C., Barter, P., Davidson, M., Kastelein, J., Koenig, W., Mcguire, D., Mozaffarian, D., et al (2018). Assessment of Omega-3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale and Design of the STRENGTH Trial. Clinical Cardiology, 41(10), 1281-1288. [More Information]
• Barter, P., Cochran, B., Rye, K. (2018). CETP inhibition, statins and diabetes. Atherosclerosis, 278, 143-146. [More Information]
• Shrestha, S., Wu, B., Guiney, L., Barter, P., Rye, K. (2018). Cholesteryl ester transfer protein and its inhibitors. Journal of Lipid Research, 59(5), 772-783. [More Information]
• Barter, P., Rye, K. (2018). Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk. Cardiology Clinics, 36(2), 299-310. [More Information]
• Alshamiri, M., Ghanaim, M., Barter, P., Chang, K., Li, J., Matawaran, B., Santoso, A., Shaheen, S., Suastika, K., Thongtang, N., et al (2018). Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East. International Journal of General Medicine, 11, 313-322. [More Information]
• Barter, P. (2018). High- Versus Low-Dose Statin: Effects on Cardiovascular Events and All-Cause Death. Circulation, 137(19), 2013-2015. [More Information]
• Karlson, B., Nicholls, S., Lundmand, P., Barter, P., Palmer, M. (2018). Modeling Statin-Induced Reductions of Cardiovascular Events in Primary Prevention: A VOYAGER Meta-Analysis. Cardiology, 140(1), 30-34. [More Information]
• Ong, K., Waters, D., Fayyad, R., Vogt, L., Melamed, S., DeMicco, D., Rye, K., Barter, P. (2018). Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. Journal of the American Heart Association, 7(2), 1-7. [More Information]
• Hui, T., McClelland, R., Allison, M., Rodriguez, C., Kronmal, R., Heckbert, S., Michos, E., Barter, P., Rye, K., Ong, K. (2018). The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 269, 86-91. [More Information]
• Choteau, S., Cuesta Torres, L., Barraclough, J., Elder, A., Martinez, G., Chen Fan, W., Shrestha, S., Ong, K., Barter, P., Celermajer, D., et al (2018). Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease. International Journal of Cardiology, 253, 138-144. [More Information]
• Vallejo-Vaz, A., Fayyad, R., Boekholdt, S., Hovingh, G., Kastelein, J., Melamed, S., Barter, P., Waters, D., Ray, K. (2018). Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 138(8), 770-781. [More Information]
• Barter, P., Waters, D. (2018). Variations in time to benefit among clinical trials of cholesterol-lowering drugs. Journal of Clinical Lipidology, 12(4), 857-862. [More Information]

2017

• Ong, K., O'Connell, R., Januszewski, A., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Waldman, B., Simes, R., Rye, K., Keech, A., et al (2017). Baseline circulating FGF21 concentrations and increase after fenofibrate treatment predict more rapid glycemic progression in type 2 diabetes: Results from the FIELD study. Clinical Chemistry, 63(7), 1261-1270. [More Information]
• Cochran, B., Ryder, W., Parmar, A., Klaeser, K., Reilhac, A., Angelis, G., Meikle, S., Barter, P., Rye, K. (2017). Determining glucose metabolism kinetics using 18F-FDG micro-PET/CT. Journal of Visualized Experiments, May 2017(123), 1-6. [More Information]
• Wu, B., Li, Y., Ong, K., Sun, Y., Shrestha, S., Hou, L., Johns, D., Barter, P., Rye, K. (2017). Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition. Arteriosclerosis, Thrombosis, and Vascular Biology, 37(12), 2333-2341. [More Information]
• Pandzic, E., Gelissen, I., Whan, R., Barter, P., Sviridov, D., Gaus, K., Rye, K., Cochran, B. (2017). The ATP binding cassette transporter, ABCG1, localizes to cortical actin filaments. Scientific Reports, 7, 1-10. [More Information]

2016

• Puranik, R., Bao, B., Bonin, A., Kaur, R., Weder, J., Casbolt, L., Hambley, T., Lay, P., Barter, P., Rye, K. (2016). A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo. Cell and Bioscience, 6(1), 1-7. [More Information]
• Tabet, F., Torres, L., Ong, K., Shrestha, S., Choteau, S., Barter, P., Clifton, P., Rye, K. (2016). High-density lipoprotein-associated miR-223 is altered after diet-induced weight loss in overweight and obese males. PloS One, 11(3). [More Information]
• Cochran, B., Hou, L., Manavalan, A., Moore, B., Tabet, F., Sultana, A., Cuesta Torres, L., Tang, S., Shrestha, S., et al, Barter, P., Rye, K. (2016). Impact of perturbed pancreatic (beta)-cell cholesterol homeostasis on adipose tissue and skeletal muscle metabolism. Diabetes, 65(12), 3610-3620. [More Information]
• Cochran, B., Ryder, W., Parmar, A., Tang, S., Reilhac, A., Arthur, A., Charil, A., Hamze, H., Barter, P., Kritharides, L., Meikle, S., Rye, K., et al (2016). In vivo PET imaging with [18F]FDG to explain improved glucose uptake in an apolipoprotein A-I treated mouse model of diabetes. Diabetologia, 59(9), 1977-1984. [More Information]
• Sultana, A., Cochran, B., Tabet, F., Patel, M., Cuesta Torres, L., Barter, P., Rye, K. (2016). Inhibition of inflammatory signaling pathways in 3T3-L1 adipocytes by apolipoprotein A-I. The FASEB Journal, 30(6), 2324-2335. [More Information]

2015

• Bisoendial, R., Tabet, F., Tak, P., Petrides, F., Torres, L., Hou, L., Cook, A., Barter, P., Weninger, W., Rye, K. (2015). Apolipoprotein A-I Limits the Negative Effect of Tumor Necrosis Factor on Lymphangiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(11), 2443-2450. [More Information]
• Wu, B., Shrestha, S., Ong, K., Johns, D., Hou, L., Barter, P., Rye, K. (2015). Cholesteryl ester transfer protein inhibition enhances endothelial repair and improves endothelial function in the rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 35(3), 628-636. [More Information]
• Sullivan, D., Watts, G., Nicholls, S., Barter, P., Grenfell, R., Chow, C., Tonkin, A., Keech, A. (2015). Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review. Heart, Lung, and Circulation, 24(5), 495-502. [More Information]
• Wu, B., Shrestha, S., Ong, K., Johns, D., Dunn, L., Hou, L., Barter, P., Rye, K. (2015). Increasing HDL levels by inhibiting cholesteryl ester transfer protein activity in rabbits with hindlimb ischemia is associated with increased angiogenesis. International Journal of Cardiology, 199, 204-212. [More Information]
• Ong, K., Januszewski, A., O'Connell, R., Buizen, L., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Scott, R., Taskinen, M., Rye, K., Keech, A. (2015). Relationship of fibroblast growth factor 21 with baseline and new on-study microvascular disease in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 59(8), 2035-2044. [More Information]
• Ong, K., Ding, J., McClelland, R., Cheung, B., Criqui, M., Barter, P., Rye, K., Allison, M. (2015). Relationship of pericardial fat with biomarkers of inflammation and hemostasis, and cardiovascular disease: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 239(2), 386-392. [More Information]
• Ong, K., Ding, J., McClelland, R., Cheung, B., Criqui, M., Barter, P., Rye, K., Allison, M. (2015). Relationship of pericardial fat with lipoprotein distribution: The Multi-Ethnic study of atherosclerosis. Atherosclerosis, 241(2), 664-670. [More Information]
• Ong, K., Januszewski, A., O'Connell, R., Jenkins, A., Xu, A., Sullivan, D., Barter, P., Hung, W., Scott, R., Taskinen, M., Keech, A., Rye, K. (2015). The relationship of fibroblast growth factor 21 with cardiovascular outcome events in the Fenofibrate Intervention and Event Lowering in Diabetes study. Diabetologia, 58(3), 464-473. [More Information]

2014

• Cochrane, B., Bisoendial, R., Hou, L., Glaros, E., Rossy, J., Thomas, S., Barter, P., Rye, K. (2014). Apolipoprotein a-I increases Insulin Secretion and Production from Pancreatic β-cells via a G-protein-cAMP-PKA-FoxO1- Dependent Mechanism. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(10), 2261-2267. [More Information]
• Ong, K., Barter, P., Waters, D. (2014). Cardiovascular drugs that increase the risk of new-onset diabetes. American Heart Journal, 167(4), 421-428. [More Information]
• Ong, K., Waters, D., Messig, M., DeMicco, D., Rye, K., Barter, P. (2014). Effect of Change in Body Weight on Incident Diabetes Mellitus in Patients With Stable Coronary Artery Disease Treated With Atorvastatin (from the Treating to New Targets Study). American Journal of Cardiology, 113(10), 1593-1598. [More Information]
• Tabet, F., Vickers, K., Cuesta Torres, L., Wiese, C., Shoucri, B., Lambert, G., Catherinet, C., Prado-Lourenco, L., Levin, M., Thacker, S., Barter, P., Rye, K., et al (2014). HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nature Communications, 5, 1-14. [More Information]
• McGrath, K., Li, X., Whitworth, P., Kasz, R., Tan, J., McLennan, S., Celermajer, D., Barter, P., Rye, K., Heather, A. (2014). High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation. Journal of Lipid Research, 55(3), 421-430. [More Information]
• Wu, B., Ong, K., Shrestha, S., Chen, K., Tabet, F., Barter, P., Rye, K. (2014). Inhibition of Arthritis in the Lewis Rat by Apolipoprotein A-I and Reconstituted High-Density Lipoproteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 34(3), 543-551. [More Information]
• Ong, K., McClelland, R., Rye, K., Cheung, B., Post, W., Vaidya, D., Criqui, M., Cushman, M., Barter, P., Allison, M. (2014). The relationship between insulin resistance and vascular calcification in coronary arteries, and the thoracic and abdominal aorta: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis, 236(2), 257-262. [More Information]
• Ong, K., Allison, M., Cheung, B., Wu, B., Barter, P., Rye, K. (2014). The Relationship between Total Bilirubin Levels and Total Mortality in Older Adults: The United States National Health and Nutrition Examination Survey (NHANES) 1999-2004. PloS One, 9(14), 1-8. [More Information]

2013

• Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2013). Arthritis: Its prevalence, risk factors, and association with cardiovascular diseases in the United States, 1999 to 2008. Annals of Epidemiology, 23(2), 80-86. [More Information]
• Wu, B., Chen, K., Shrestha, S., Ong, K., Barter, P., Rye, K. (2013). High Density Lipoproteins Inhibit Vascular Endothelial Inflammation by Increasing 3[beta]-Hydroxysteroid-{Delta}24 Reductase Expression and Inducing Heme Oxygenase-1. Circulation Research, 112(2), 278-288. [More Information]
• Ong, K., Allison, M., Cheung, B., Wu, B., Barter, P., Rye, K. (2013). Trends in C-Reactive Protein Levels in US Adults From 1999 to 2010. American Journal of Epidemiology, 177(12), 1430-1442. [More Information]

2012

• Nicholls, S., Gordon, A., Johannson, J., Ballantyne, C., Barter, P., Brewer, H., Kastelein, J., Wong, N., Borgman, M., Nissen, S. (2012). ApoA-I Induction as a Potential Cardioprotective Strategy: Rationale for the SUSTAIN and ASSURE Studies. Cardiovascular Drugs and Therapy, 26(2), 181-187. [More Information]
• Morales-Villegas, E., Moreno-Virgen, G., Barter, P. (2012). CETP pharmacological manipulation transforming human into mouse: Is this still a viable hypothesis? Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry, 12(4), 266-278. [More Information]
• Barter, P., Rye, K. (2012). Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. Journal of Lipid Research, 53(9), 1755-1766. [More Information]
• Ong, K., Rye, K., O'Connell, R., Jenkins, A., Brown, C., Xu, A., Sullivan, D., Barter, P., Keech, A. (2012). Long-Term Fenofibrate Therapy Increases Fibroblast Growth Factor 21 and Retinol-Binding Protein 4 in Subjects with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 97(12), 4701-4708. [More Information]
• Wu, B., Chen, K., Barter, P., Rye, K. (2012). Niacin Inhibits Vascular Inflammation via the Induction of Heme Oxygenase-1. Circulation, 125(1), 150-158. [More Information]
• Tso, C., Rye, K., Barter, P. (2012). Phenotypic and functional changes in blood monocytes following adherence to endothelium. PloS One, 7(5), 1-11. [More Information]
• Huijgen, R., Boekholdt, S., Arsenault, B., Bao, W., Davaine, J., Tabet, F., Petrides, F., Rye, K., DeMicco, D., Barter, P., et al (2012). Plasma PCSK9 Levels and Clinical Outcomes in the TNT (Treating to New Targets) Trial: A Nested Case-Control Study. Journal of the American College of Cardiology, 59(20), 1778-1784. [More Information]
• Rye, K., Barter, P. (2012). Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochimica et Biophysica Acta. Molecular and Cell Biology of Lipids, 1821 (3), 473-480. [More Information]
• Barter, P., Rye, K., Beltangady, M., Ports, W., Duggan, W., Boekholdt, S., DeMicco, D., Kastelein, J., Shear, C. (2012). Relationship between atorvastatin dose and the harm caused by torcetrapib. Journal of Lipid Research, 53(11), 2436-2442. [More Information]
• Arsenault, B., Boekholdt, S., Hovingh, G., Hyde, C., DeMicco, D., Chatterjee, A., Barter, P., Deedwania, P., Waters, D., LaRosa, J., et al (2012). The 719Arg Variant of KIF6 and Cardiovascular Outcomes in Statin-Treated, Stable Coronary Patients of the Treating to New Targets and Incremental Decrease in End Points Through Aggressive Lipid-Lowering Prospective Studies. Circulation Cardiovascular Genetics, 5(1), 51-57. [More Information]
• Drew, B., Rye, K., Duffy, S., Barter, P., Kingwell, B. (2012). The emerging role of HDL in glucose metabolism. Nature Reviews Endocrinology, 8(4), 237-245. [More Information]
• Rye, K., Barter, P. (2012). The inhibition of cholesteryl ester transfer protein: a long and winding road. Journal of Lipid Research, 53(6), 1039-1041. [More Information]

2011

• Ong, K., Wu, B., Cheung, B., Barter, P., Rye, K. (2011). Association of lower total bilirubin level with statin usage: The United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis, 219(2), 728-733. [More Information]
• Barter, P., Rye, K. (2011). Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: where are we now? Trends In Pharmacological Sciences, 32(12), 694-699. [More Information]
• Chan, J., Chan, S., Deerochanawong, C., Go, R., Lee, K., Ma, R., Pan, C., Sheu, W., Barter, P. (2011). Diabetic dyslipidaemia in Asian populations in the Western Pacific Region: What we know and don't know. Diabetes Research and Clinical Practice, 94(1), 1-13. [More Information]
• Barter, P., Rye, K., Tardif, J., Waters, D., Boekholdt, S., Breazna, A., Kastelein, J. (2011). Effect of Torcetrapib on Glucose, Insulin, and Hemoglobin A1c in Subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) Trial. Circulation, 124(5), 555-562. [More Information]
• Nicholls, S., Ballantyne, C., Barter, P., Chapman, M., Erbel, R., Libby, P., Raichlen, J., Uno, K., Borgman, M., Wolski, K., et al (2011). Effect of Two Intensive Statin Regimens on Progression of Coronary Disease. New England Journal of Medicine, 365(22), 2078-2087. [More Information]
• Watts, G., Sullivan, D., Poplawski, N., van Bockxmeer, F., Hamilton-Craig, I., Clifton, P., O'Brien, R., Bishop, W., George, P., Barter, P., Freeman, L., Krass, I., Trent, R., et al (2011). Familial hypercholesterolaemia: A model of care for Australasia. Atherosclerosis Supplements, 12(2), 221-263. [More Information]
• Barter, P. (2011). HDL-C: Role as a risk modifier. Atherosclerosis Supplements, 12(3), 267-270. [More Information]
• Nicholls, S., Borgman, M., Nissen, S., Raichlen, J., Ballantyne, C., Barter, P., Chapman, M., Erbel, R., Libby, P. (2011). Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: Effect of Rosuvastatin versus AtorvastatiN). Current Medical Research and Opinion, 27(6), 1119-1129. [More Information]
• Reimers, G., Jackson, C., Rickards, J., Chan, P., Cohn, J., Rye, K., Barter, P., Rodgers, K. (2011). Inhibition of rupture of established atherosclerotic plaques by treatment with apolipoprotein A-I. Cardiovascular Research, 91(1), 37-44. [More Information]
• Tabet, F., Lambert, G., Torres, L., Hou, L., Sotirchos, I., Touyz, R., Jenkins, A., Barter, P., Rye, K. (2011). Lipid-Free Apolipoprotein A-I and Discoidal Reconstituted High-Density Lipoproteins Differentially Inhibit Glucose-Induced Oxidative Stress in Human Macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology, 31(5), 1192-1200. [More Information]
• Arsenault, B., Barter, P., DeMicco, D., Bao, W., Preston, G., LaRosa, J., Grundy, S., Deedwania, P., Greten, H., Wenger, N., et al (2011). Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. Journal of the American College of Cardiology, 57(1), 63-69. [More Information]
• Waters, D., Ho, J., DeMicco, D., Breazna, A., Arsenault, B., Wun, C., Kastelein, J., Colhoun, H., Barter, P. (2011). Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. Journal of the American College of Cardiology, 57(14), 1535-1545. [More Information]
• Barter, P. (2011). Raising HDL-C can be achieved by both lifestyle changes and pharmacological means. Introduction. Atherosclerosis Supplements, 12(3), 265-266. [More Information]
• Ong, K., Barter, P., Rye, K. (2011). Response to statin use and serum bilirubin levels. Atherosclerosis, 219(2), 392-392. [More Information]
• Preiss, D., Seshasai, S., Welsh, P., Murphy, S., Ho, J., Waters, D., DeMicco, D., Barter, P., Cannon, C., Sabatine, M., et al (2011). Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 305(24), 2556-2564. [More Information]
• Di Bartolo, B., Nicholls, S., Bao, B., Rye, K., Heather, A., Barter, P., Bursill, C. (2011). The apolipoprotein A-I mimetic peptide ETC-642 exhibits anti-inflammatory properties that are comparable to high density lipoproteins. Atherosclerosis, 217(2), 395-400. [More Information]
• Di Bartolo, B., Vanags, L., Tan, J., Bao, B., Rye, K., Barter, P., Bursill, C. (2011). The apolipoprotein A-I mimetic peptide, ETC-642, reduces chronic vascular inflammation in the rabbit. Lipids in Health and Disease, 10(NOvember), A224-1-A224-8. [More Information]
• Barter, P. (2011). The causes and consequences of low levels of high density lipoproteins in patients with diabetes. Journal of Diabetes & Metabolism, 35(2), 101-106. [More Information]

2010

• Taskinen, M., Barter, P., Ehnholm, C., Sullivan, D., Robledo, K., Simes, R., Best, J., Hamwood, S., Keech, A. (2010). Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes. Diabetologia, 53(9), 1846-1855. [More Information]
• Patel, S., Di Bartolo, B., Nakhla, S., Heather, A., Mitchell, T., Jessup, W., Celermajer, D., Barter, P., Rye, K. (2010). Anti-inflammatory effects of apolipoprotein A-I in the rabbit. Atherosclerosis, 212(2), 392-397. [More Information]
• Barter, P., Brandrup-Wognsen, G., Palmer, M., Nicholls, S. (2010). Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. Journal of Lipid Research, 51(6), 1546-1553. [More Information]
• Fryirs, M., Barter, P., Appavoo, M., Tuch, B., Tabet, F., Heather, A., Rye, K. (2010). Effects of High-Density Lipoproteins on Pancreatic {beta}-Cell Insulin Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(8), 1642-1648. [More Information]
• Wu, B., Yan, L., Charlton, F., Witting, P., Barter, P., Rye, K. (2010). Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(5), 968-975. [More Information]
• Laurila, P., Naukkarinen, J., Ripatti, S., Kauttu, T., Silander, K., Salomaa, V., Perola, M., Karhunen, P., Barter, P., Ehnholm, C., et al (2010). Genetic Association and Interaction Analysis of USF1 and APOA5 on Lipid Levels and Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(2), 346-352. [More Information]
• Waterworth, D., Ricketts, S., Song, K., Chen, L., Zhao, J., Ripatti, S., Aulchenko, Y., Zhang, W., Yuan, X., Lim, N., et al (2010). Genetic variants influencing circulating lipid levels and risk of coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(11), 2264-2276. [More Information]
• Bursill, C., Castro, M., Beattie, D., Nakhla, S., van der Vorst, E., Heather, A., Barter, P., Rye, K. (2010). High-Density Lipoproteins Suppress Chemokines and Chemokine Receptors In Vitro and In Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(9), 1773-1778. [More Information]
• Nicholls, S., Brandrup-Wognsen, G., Palmer, M., Barter, P. (2010). Meta-analysis of comparative efficacy of increasing dose of Atorvastatin versus Rosuvastatin versus Simvastatin on lowering levels of atherogenic lipids (from VOYAGER). American Journal of Cardiology, 105(1), 69-76. [More Information]
• Nobecourt, E., Tabet, F., Lambert, G., Puranik, R., Bao, B., Yan, L., Davies, M., Brown, B., Jenkins, A., Dusting, G., Barter, P., Rye, K., et al (2010). Nonenzymatic Glycation Impairs the Antiinflammatory Properties of Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(4), 766-772. [More Information]
• Cannon, C., Shah, S., Dansky, H., Davidson, M., Brinton, E., Gotto Jnr, A., Stepanavage, M., Liu, S., Gibbons, P., Ashraf, T., Barter, P., et al (2010). Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine, 363(25), 2406-2415. [More Information]
• Tabet, F., Remaley, A., Segaliny, A., Millet, J., Yan, L., Nakhla, S., Barter, P., Rye, K., Lambert, G. (2010). The 5A Apolipoprotein A-I Mimetic Peptide Displays Antiinflammatory and Antioxidant Properties In Vivo and In Vitro. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(2), 246-252. [More Information]
• Barter, P. (2010). The Relationship between Cholesteryl Ester Transfer Protein and Cardiovascular Risk. Clinical Chemistry, 56(10), 1547-9. [More Information]

2009

• Patel, S., Puranik, R., Nakhla, S., Lundmand, P., Stocker, R., Wang, X., Lambert, G., Rye, K., Barter, P., Nicholls, S., Celermajer, D. (2009). Acute hypertriglyceridaemia in humans increases the triglyceride content and decreases the anti-inflammatory capacity of high density lipoproteins. Atherosclerosis, 204(2), 424-428. [More Information]
• Fryirs, M., Barter, P., Rye, K. (2009). Cholesterol metabolism and pancreatic B-cell function. Current Opinion in Lipidology, 20(3), 159-164. [More Information]
• Barter, P. (2009). Evolving Targets of Therapy. In Christie M Ballantyne (Eds.), Clinical Lipidology: A Companion to Braunwalds Heart Disease, (pp. 387-395). Philadelphia, USA: Saunders Elsevier.
• Ling, H., Waterworth, D., Stirnadel, H., Pollin, T., Barter, P., Kesaniemi, Y., Mahley, R., McPherson, R., Waeber, G., Bersot, T., et al (2009). Genome-wide linkage and association analyses to identify genes influencing adiponectin levels: the GEMS Study. Obesity, 17(4), 737-744. [More Information]
• Barter, P., Rye, K. (2009). High-density lipoprotein as a therapeutic target. In Tonkin, Andrew (Eds.), Therepeutic Strategies: Lipid Disorders, (pp. 29-42). United Kingdom: Clinical Publishing, Oxford.
• Barter, P. (2009). Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. American Journal of Cardiology, 104(10 Suppl), 10E-15E. [More Information]
• Chirovsky, D., Fedirko, V., Cui, Y., Sazonov, V., Barter, P. (2009). Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. European Journal of Cardiovascular Prevention and Rehabilitation, 16(4), 404-423. [More Information]
• Patel, S., Drew, B., Nakhla, S., Duffy, S., Murphy, A., Barter, P., Rye, K., Chin-Dusting, J., Hoang, A., Sviridov, D., Celermajer, D., et al (2009). Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. Journal of the American College of Cardiology, 53(11), 962-971. [More Information]
• Peshavariya, H., Dusting, G., Di Bartolo, B., Rye, K., Barter, P., Jiang, F. (2009). Reconstituted high-density lipoprotein suppresses leukocyte NADPH oxidase activation by disrupting lipid rafts. Free Radical Research, 43(8), 772-782. [More Information]
• Taskinen, M., Sullivan, D., Ehnholm, C., Whiting, M., Zannino, D., Simes, R., Keech, A., Barter, P. (2009). Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 950-955. [More Information]
• McGrath, K., Li, X., Puranik, R., Liong, E., Tan, J., Dy, V., Di Bartolo, B., Barter, P., Rye, K., Heather, A. (2009). Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 29(6), 877-882. [More Information]
• Rye, K., Bursill, C., Lambert, G., Tabet, F., Barter, P. (2009). The metabolism and anti-atherogenic properties of HDL. Journal of Lipid Research, 50(Supplement), S195-S200. [More Information]

2008

• Rye, K., Barter, P. (2008). Antiinflammatory Actions of HDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(11), 1890-1891. [More Information]
• Tabet, F., Barter, P., Rye, K. (2008). Apolipoprotein A-I and Reconstituted High-Density Lipoproteins Inhibit NADPH Oxidase Activation and Expression and Increase Superoxide Dismutase Levels in Human Macrophages in High Glucose Conditions. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(6), e-87.
• Barter, P., Ginsberg, H. (2008). Effectiveness of Combined Statin Plus Omega-3 Fatty Acid Therapy for Mixed Dyslipidemia. American Journal of Cardiology, 102(8), 1040-1045. [More Information]
• Nobécourt, E., Zeng, J., Davies, M., Bronwyn, B., Yadav, S., Barter, P., Rye, K. (2008). Effects of cross-link breakers, glycation inhibitors and insulin sensitisers on HDL function and the non-enzymatic glycation of apolipoprotein A-I. Diabetologia, 51(6), 1008-1017. [More Information]
• Stirnadel, H., Lin, X., Ling, H., Song, K., Barter, P., Kesaniemi, Y., Mahley, R., McPherson, R., Waeber, G., Bersot, T., et al (2008). Genetic and phenotypic architecture of metabolic syndrome-associated components in dyslipidemic and normolipidemic subjects: The GEMS Study. Atherosclerosis, 197(2), 868-876. [More Information]
• Homer, V., Marais, A., Charlton, F., Laurie, A., Hurndell, N., Scott, R., Mangili, F., Sullivan, D., Barter, P., Rye, K., et al (2008). Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa. Atherosclerosis, 196(2), 659-666. [More Information]
• Di Bartolo, B., Bao, B., Rye, K., Nicholls, S., Barter, P. (2008). In Vivo Properties of a Novel Apolipoprotein A-1 Mimetic Peptide. Journal of the American College of Cardiology, 51(10), A283.
• Shah, S., Waters, D., Barter, P., Kastelein, J., Shepherd, J., Wenger, N., DeMicco, D., Breazna, A., LaRosa, J. (2008). Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery. Journal of the American College of Cardiology, 51(20), 1938-1943. [More Information]
• Barter, P., Rye, K. (2008). Is There a Role for Fibrates in the Management of Dyslipidemia in the Metabolic Syndrome? Arteriosclerosis, Thrombosis, and Vascular Biology, 28(1), 39-46. [More Information]
• Sandhu, M., Waterworth, D., Debenham, S., Wheeler, E., Papadakis, K., Zhao, J., Song, K., Yuan, X., Johnson, T., Ashford, S., Barter, P., et al (2008). LDL-cholesterol concentrations: a genome-wide association study. The Lancet, 371(9611), 483-491. [More Information]
• Kastelein, J., van der Steeg, W., Holme, I., Gaffney, M., Cater, N., Barter, P., Deedwania, P., Olsson, A., Boekholdt, S., DeMicco, D., et al (2008). Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment. Circulation, 117(23), 3002-3009. [More Information]
• Puranik, R., Bao, B., Nobecourt, E., Nicholls, S., Dusting, G., Barter, P., Celermajer, D., Rye, K. (2008). Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis, 196(1), 240-247. [More Information]
• Lambert, G., Ancellin, N., Charlton, F., Comas, D., Pilot, J., Keech, A., Patel, S., Sullivan, D., Cohn, J., Rye, K., Barter, P. (2008). Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment. Clinical Chemistry, 54(6), 1038-1045. [More Information]
• Settasatian, N., Barter, P., Rye, K. (2008). Remodeling of apolipoprotein E-containing spherical reconstituted high density lipoproteins by phospholipid transfer protein. Journal of Lipid Research, 49(1), 115-126. [More Information]

2007

• Kastelein, J., Barter, P. (2007). A comparison of the association of on-treatment lipid and apolipoprotein parameters to cardiovascular events in ideal and TNT. Atherosclerosis Supplements, 8, 196.
• Patel, S., Drew, B., Duffy, S., Nahkla, S., Rye, K., Barter, P., Celermajer, D., Kingwell, B. (2007). Abstract 1047: Infusion of Reconstituted High Density Lipoproteins Into Humans Enhances the In Vitro Anti-Inflammatory Capacity of the High Density Lipoprotein Fraction. Circulation, 116, II_209.
• Scott, R., D'Emden, M., Best, J., Drury, P., Ehnholm, C., Kesaniemi, Y., Pardy, C., Tse, D., Barter, P., Taskinen, M., Copt, S., Keech, A., et al (2007). Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate. Circulation, 116, II_838.
• Barter, P., Shear, C. (2007). Aggressive Management of Obesity in Children and Young Adults: The Known Challenges and Potential Opportunities. Clinical Pharmacology & Therapeutics, 81(5), 627-630. [More Information]
• Kastelein, J., van Leuven, S., Burgess, L., Evans, G., Kuivenhoven, J., Barter, P., Revkin, J., Grobbee, D., Riley, W., Shear, C., et al (2007). Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal of Medicine, 356, 1620-1630. [More Information]
• Barter, P., Caulfield, M., Eriksson, M., Grundy, S., Kastelein, J., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J., Waters, D., et al (2007). Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England Journal of Medicine, 357(21), 2109-2122. [More Information]
• Barter, P., Rye, K. (2007). HDL and Atherosclerosis. In Christopher J Fielding (Eds.), High Density Lipoproteins: From Basic Biology to Clinical Aspects, (pp. 491-505). Germany: Wiley - V C H Verlag GmbH & Co. KGaA. [More Information]
• Barter, P., Gotto, A., laRosa, J., Maroni, J., Szarek, M., Grundy, S., Kastelein, J., Bittner, V., Fruchart, J. (2007). HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. New England Journal of Medicine, 357(13), 1301-1310. [More Information]
• Barter, P., Rye, K. (2007). HDL structure and metabolism: Its regulation by cell membrane receptors. In C J Packard (Eds.), The Year in Lipid Disorders. Volume 1, (pp. 93-112). United Kingdom: Clinical Publishing, Oxford.
• Homer, V., Marais, A., Laurie, A., Charlton, F., Sullivan, D., Barter, P., Rye, K., George, P., Lambert, G. (2007). Identification and Molecular Characterization of New PCSK9 Missense Mutations Associated with Familial Hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(6), e-122.
• Balkau, B., Deanfield, J., Despres, J., Bassand, J., Fox, K., Smith, S., Barter, P., Tan, C., Van Gaal, L., Wittchen, H., et al (2007). International Day for the Evaluation of Abdominal Obesity (IDEA): A Study of Waist Circumference, Cardiovascular Disease, and Diabetes Mellitus in 168 000 Primary Care Patients in 63 Countries. Circulation, 116(17), 1942-1951. [More Information]
• Skropeta, D., Settasatian, C., McMahon, M., Shearston, K., Caiazza, D., McGrath, K., Jin, W., Rader, D., Barter, P., Rye, K. (2007). N-Glycosylation regulates endothelial lipase-mediated phospholipid hydrolysis in apoE- and apoA-I-containing high density lipoproteins. Journal of Lipid Research, 48(9), 2047-2057. [More Information]
• Barter, P., Puranik, R., Rye, K. (2007). New insights into the role of HDL as an antiinflammatory agent in the prevention of cardiovascular disease. Current Cardiology Reports, 9(6), 493-498. [More Information]
• Barter, P., McPherson, Y., Song, K., Kesaeniemi, Y., Mahley, R., Waeber, G., Bersot, T., Mooser, V., Waterworth, D., Grundy, S. (2007). Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. The Journal of Clinical Endocrinology and Metabolism, 92(6), 2041-2045. [More Information]
• Barter, P. (2007). Targeting Cholesterol Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. International Journal of Cardiology, 122(Suppl 1), S9.
• Nobecourt, E., Davies, M., Brown, B., Curtiss, L., Bonnet, D., Charlton, F., Januszewski, A., Jenkins, A., Barter, P., Rye, K. (2007). The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia, 50(3), 643-653. [More Information]
• Barter, P. (2007). Torcetrapib - Final results of the ILLUMINATE trial. Circulation, 116(22), 2630.

2006

• Puranik, R., Bao, B., Celermajer, D., Rye, K., Barter, P., Nicholls, S., Nobecourt, E. (2006). A single infusion of lipid free apo A1 can rescue vascular inflammation. Atherosclerosis Supplements, 7, 153.
• Puranik, R., Nobecourt, E., Bao, B., Davies, M., Barter, P., Celermajer, D., Rye, K. (2006). Abstract 1355: The Impact of Glycation on the Anti-inflammatory Properties of High Density Lipoproteins in vivo. Circulation, 114, II-257-II-258.
• Kastelein, J., Holme, I., Barter, P., Olsson, A., Cater, N., DeMicco, D., Gaffney, M., Szarek, M., LaRosa, J., Pedersen, T. (2006). Abstract 3357: Superiority of ApoB/ApoA1 Ratio for Predicting Cardiovascular Risk in Pooled Analyses of the Incremental Decrease in Endpoints through Aggressive Lipid-Lowering (IDEAL) and Treating to New Targets (TNT) Trials. Circulation, 114, II_713-II_714.
• Deedwania, P., Barter, P., Carmena, R., Fruchart, J., Haffner, S., Shepherd, J., Treating to New Targets, (. (2006). Aggressive lipid lowering with atorvastatin reduces increased risk of cardiovascular events in patients with metabolic syndrome and coronary heart disease. European Heart Journal, 27(Suppl 1), 931-932.
• Barter, P., Ballantyne, C., Carmena, R., Castro Cabezas, M., Chapman, M., Couture, P., De Graaf, J., Durrington, P., Faergeman, O., Frohlich, J., et al (2006). Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. Journal of Internal Medicine, 259(3), 247-258. [More Information]
• Barter, P., Rye, K. (2006). Are we lowering LDL cholesterol sufficiently? Nature Clinical Practice Cardiovascular Medicine, 3(6), 290-291. [More Information]
• Barter, P., Rye, K. (2006). Cardioprotective Properties of Fibrates: Which Fibrate, Which Patients, What Mechanism? Circulation, 113(12), 1553-1555. [More Information]
• Teo, K., Nicholls, S., Kee, P., Rye, K., Barter, P. (2006). Combination high-density lipoprotein infusion and atorvastatin significantly reduces experimental atherosclerosis compared to either therapy alone: serial analysis with high-resolution MRI. European Heart Journal, 27(Suppl 1), 973-974.
• Nicholls, S., Lundman, P., Harmer, J., Cutri, B., Griffiths, K., Rye, K., Barter, P., Celermajer, D. (2006). Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. Journal of the American College of Cardiology, 48(4), 715-720. [More Information]
• Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). Correction to the FIELD study report. The Lancet, 368(9545), 1415. [More Information]
• Barrett, P., Barter, P. (2006). Effect of inhibiting cholesteryl ester transfer protein on the kinetics of HDL cholesteryl ester transport in plasma: In vivo studies in rabbits. Atherosclerosis Supplements, 7, 322.
• Waters, D., Barter, P., Kastelein, J., Shah, S., Shepherd, J., Wenger, N., LaRosa, J., Treating to New Targets, (. (2006). Effect of intensive cholesterol lowering with atorvastatin in patients with previous coronary bypass surgery: a Treating to New Targets (TNT) substudy. European Heart Journal, 27(Suppl 1), 943.
• Shepherd, J., Barter, P., Carmena, R., Deedwania, P., Fruchart, J., Haffner, S., Hsia, J., Breazna, A., LaRosa, J., Grundy, S., et al (2006). Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes - The treating to new targets (TNT) study. Diabetes Care, 29(6), 1220-1226. [More Information]
• Waters, D., LaRosa, J., Barter, P., Fruchart, J., Gotto Jnr, A., Carter, R., Breazna, A., Kastelein, J., Grundy, S. (2006). Effects of High-Dose Atorvastatin on Cerebrovascular Events in Patients With Stable Coronary Disease in the TNT (Treating to New Targets) Study. Journal of the American College of Cardiology, 48(9), 1793-1799. [More Information]
• Nobecourt, E., Puranik, R., Bao, B., Davies, M., Barter, P., Rye, K. (2006). Evidence that glycation of apolipoprotein. XIV International Symposium on Atherosclerosis, Ireland: Elsevier Ireland Ltd.
• Nobecourt, E., Puranik, R., Bao, B., Davies, M., Barter, P., Rye, K. (2006). Evidence that glycation of apolipoprotein A-I inhibits the anti-inflammatory properties of HDL in vivo. Atherosclerosis Supplements, 7, 71.
• Hime, N., Drew, K., Wee, K., Barter, P., Rye, K. (2006). Formation of high density lipoproteins containing both apolipoprotein A-I and A-II in the rabbit. Journal of Lipid Research, 47(1), 115-122. [More Information]
• Barter, P. (2006). From metabolic syndrome to cardiometabolic risk: The common ground. Atherosclerosis Supplements, 7, 341.
• Rye, K., Barter, P., Bao, B. (2006). HDL and the inhibition of inflammation in vivo. Atherosclerosis Supplements, 7, 152.
• Heather, A., Barter, P. (2006). HDL exerts novel anti-inflammatory effects on endothelial cells via the suppression of NFkB. Atherosclerosis Supplements, 7, 232.
• Tso, C., Martinic, G., Fan, W., Rogers, C., Rye, K., Barter, P. (2006). High-density lipoproteins enhance progenitor-mediated endothelium repair in mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(5), 1144-1149. [More Information]
• Barter, P., Rye, K. (2006). Homocysteine and Cardiovascular Disease: Is HDL the Link? Circulation Research, 99(6), 565-566. [More Information]
• Barter, P. (2006). Managing diabetic dyslipidaemia-beyond LDL-C:HDL-C and triglycerides. Atherosclerosis Supplements, 7(4), 17-21. [More Information]
• Barter, P., Gotto Jnr, A., LaRosa, J., Grundy, S., Kastelein, J., Bittner, V., Fruchart, J., Treating to New Targets, (. (2006). On-treatment Levels of HDL-C and the Ratio of LDL-C/HDL-C as Predictors of Cardiovascular Events in the Treating to New Targets (TNT) Study. Journal of the American College of Cardiology, 47(4 Suppl A), 298A.
• Barter, P. (2006). Options for therapeutic intervention: how effective are the different agents? European Heart Journal Supplements, 8(Suppl F), F47-F53. [More Information]
• Deedwania, P., Barter, P., Carmena, R., Fruchart, J., Grundy, S., Haffner, S., Kastelein, J., LaRosa, J., Schachner, H., Shepherd, J., et al (2006). Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. The Lancet, 368(9539), 919-928. [More Information]
• Rye, K., Bright, R., Psaltis, M., Barter, P. (2006). Regulation of reconstituted high density lipoprotein structure and remodeling by apolipoprotein E. Journal of Lipid Research, 47(5), 1025-1036. [More Information]
• Barter, P., Rye, K. (2006). Relationship between the concentration and antiatherogenic activity of high-density lipoproteins. Current Opinion in Lipidology, 17(4), 399-403. [More Information]
• Barter, P. (2006). Role of HDL-C and TG metabolism in abdominal obesity. Atherosclerosis Supplements, 7, 40.
• Barter, P., Kastelein, J. (2006). Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. Journal of the American College of Cardiology, 47(3), 492-499. [More Information]
• Barter, P., Rye, K. (2006). The Argument Against the Appropriateness of Over-the-Counter Statins. Circulation, 114(12), 1315-1320. [More Information]
• Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M. (2006). The FIELD study - Reply. The Lancet, 367(9517), 1142-1143. [More Information]
• Rye, K., Nobecourt, E., Puranik, R., Bao, B., Barter, P. (2006). The impact of diabetes on the anti-inflammatory properties of high density lipoproteins in vivo. European Heart Journal, 27(Suppl 1), 520.
• Barter, P., Rye, K. (2006). The rationale for using apoA-I as a clinical marker of cardiovascular risk. Journal of Internal Medicine, 259(5), 447-454. [More Information]
• Barter, P., Kastelein, J. (2006). Translating today's science into clinical practice. Atherosclerosis Supplements, 7(1 Spec. Iss.), 1-2. [More Information]

2005

• Puranik, R., Barter, P. (2005). A single infusion of lipid free Apo A1 can rescue vascular inflammation, in vivo. Circulation, 112, U320.
• Barter, P. (2005). Antiatherogenic Properties of Fibrates. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(6), 1095-1096. [More Information]
• Barter, P. (2005). Cardioprotective Effects of High-Density Lipoproteins: The Evidence Strengthens. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(7), 1305-1306. [More Information]
• Stender, S., Schuster, H., Barter, P., Watkins, C., Kallend, D. (2005). Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes, Obesity and Metabolism, 7(4), 430-438. [More Information]
• Nicholls, S., Barter, P. (2005). Consumption of saturated fat impairs endothelial function and the anti-inflammatory properties of high density lipoproteins. Circulation, 112, U435-U436.
• Nicholls, S., Celermajer, D., Rye, K., Barter, P., Griffiths, K., Cutri, B., Harmer, J., Lundman, P. (2005). Consumption of saturated fat impairs endothelial function and the antiinflammatory properties of high-density lipoproteins. Circulation, 112(17), U43.
• Kee, P., Caiazza, D., Rye, K., Barrett, P., Morehouse, L., Barter, P. (2005). Effect of Inhibiting Cholesteryl Ester Transfer Protein on the Kinetics of High-Density Lipoprotein Cholesteryl Ester Transport in Plasma: In Vivo Studies in Rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(4), 884-890. [More Information]
• Waters, D., Barter, P. (2005). Effects of intensive lipid lowering with atorvastatin on cerebrovascular events in patients with stable coronary disease: A treating to new targets (TNT) substudy. Circulation, 112, U475.
• Keech, A., Simes, R., Barter, P., Best, J., Scott, R., Taskinen, M., Forder, P., Pillai, A., Davis, T., Glasziou, P., Sullivan, D., MacMahon, S., et al (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. The Lancet, 366(9500), 1849-1861. [More Information]
• Scott, R., Best, J., Forder, P., Taskinen, M., Simes, R., Barter, P., Keech, A. (2005). Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate (ISRCTN64783481). Cardiovascular Diabetology, 4(13), 1-9. [More Information]
• Nicholls, S., Rye, K., Barter, P. (2005). High-density lipoproteins as therapeutic targets. Current Opinion in Lipidology, 16(3), 345-349. [More Information]
• Nicholls, S., Cutri, B., Worthley, S., Kee, P., Rye, K., Bao, B., Barter, P. (2005). Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(11), 2416-2421. [More Information]
• Deedwania, P., Barter, P. (2005). Intensive lipid lowering with atorvastatin in patients with metabolic syndrome and stable coronary disease. Circulation, 112, U726.
• LaRosa, J., Grundy, S., Waters, D., Shear, C., Barter, P., Fruchart, J., Gotto Jnr, A., Greten, H., Kastelein, J., Shepherd, J., et al (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 352(14), 1425-1435. [More Information]
• Barter, P. (2005). Measuring effective reductions in cholesterol using rosuvastatin therapy (Mercury I): Safety analysis from an open-label extension. Atherosclerosis Supplements, 6, 101.
• Yu, Y., Wyszynski, D., Waterworth, D., Wilton, S., Barter, P., Kesaniemi, Y., Mahley, R., McPherson, R., Waeber, G., Bersot, T., et al (2005). Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. Journal of Lipid Research, 46(10), 2202-2213. [More Information]
• Tonkin, A., Barter, P., Best, J., Boyden, A., Furler, J., Hossack, K., Sullivan, D., Thompson, P., Vale, M., Cooper, C., et al (2005). National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: position statement on lipid management--2005. Heart, Lung, and Circulation, 14(4), 275. [More Information]
• Nicholls, S., Dusting, G., Cutri, B., Bao, B., Drummond, G., Rye, K., Barter, P. (2005). Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation, 111(12), 1543-1550. [More Information]
• Wyszynski, D., Waterworth, D., Barter, P., Cohen, J., Kesaniemi, Y., Mahley, R., McPherson, R., Waeber, G., Bersot, T., Sharma, S., et al (2005). Relation Between Atherogenic Dyslipidemia and the Adult Treatment Program-III Definition of Metabolic Syndrome (Genetic Epidemiology of Metabolic Syndrome Project). American Journal of Cardiology, 95(2), 194-198. [More Information]
• Barter, P. (2005). Role of nicotinic acid in raising high-density lipoprotein cholesterol (HDL-C) to reduce cardiovascular risk: an Asian/Pacific consensus. British Journal of Diabetes and Vascular Disease, 5, 1-16.
• Barter, P. (2005). The inflammation: Lipoprotein cycle. Atherosclerosis Supplements, 6(2), 15-20. [More Information]
• Settasatian, N., Barter, P., Rye, K. (2005). The Influence of Apolipoprotein E Isoforms on High Density Lipoprotein Remodelling by Phospholipid Transfer Protein. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5), E-90.
• Barter, P. (2005). The realities of dyslipidaemia in metabolic syndrome and diabetes. British Journal of Diabetes and Vascular Disease, 5(Suppl 1), S7-S11.
• Barter, P. (2005). The role of HDL-cholesterol in preventing atherosclerotic disease. European Heart Journal Supplements, 7(F), F4-F8. [More Information]
• Settasatian, C., van der Meer, A., Rader, D., Barter, P., Rye, K. (2005). The Role of the Beta5 Loop of Endothelial Lipase in the Hydrolysis of Reconstituted High-Density Lipoprotein Phospholipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(5), E-76.
• Barter, P. (2005). Why should we target HDL to further improve CHD prevention? Atherosclerosis Supplements, 6, 177-178.

2004

• Barter, P., Nicholls, S., Rye, K., Anantharamaiah, G., Navab, M., Fogelman, A. (2004). Antiinflammatory Properties Of HDL. Circulation Research, 95(8), 764-772. [More Information]
• Nicholls, S., Barter, P., Bao, B. (2004). Apolipoprotein composition influences the ability of reconstituted high density lipoproteins to promote a stable plaque phenotype. Circulation, 110, 37.
• Hime, N., Drew, K., Hahn, C., Barter, P., Rye, K. (2004). Apolipoprotein E Enhances Hepatic Lipase-Mediated Hydrolysis Of Reconstituted High-Density Lipoprotein Phospholipid And Triacylglycerol In An Isoform-Dependent Manner. Biochemistry, 43(38), 12306-12314. [More Information]
• Colquhoun, D., Keech, A., Hunt, D., Marschner, I., Simes, R., Glasziou, P., White, H., Barter, P., Tonkin, A. (2004). Effects Of Pravastatin On Coronary Events In 2073 Patients With Low Levels Of Both Low-Density Lipoprotein Cholesterol And High-Density Lipoprotein Cholesterol: Results From The Lipid Study. European Heart Journal, 25(9), 771-777. [More Information]
• Schuster, H., Barter, P. (2004). Effects of rosuvastatin and atorvastatin on plasma lipids in Type 2 diabetes patients in the MERCURY I study. Diabetologia, 47, A409.
• Schuster, H., Barter, P., Stender, S., Cheung, R., Bonnet, J., Morrell, J., Watkins, C., Kallend, D., Raza, A. (2004). Effects Of Switching Statins On Achievement Of Lipid Goals: Measuring Effective Reductions In Cholesterol Using Rosuvastatin Therapy (Mercury I) Study. American Heart Journal, 147(4), 705-713. [More Information]
• Barter, P. (2004). Effects of switching statins on non-HDL-C in hypercholesterolaemic patients and achievement of ATP III combined LDL-C and non-HDL-C goals in patients with elevated triglycerides: Mercury I trial results. Atherosclerosis Supplements, 5, 106.
• Rye, K., Barter, P. (2004). Formation And Metabolism Of Prebeta-Migrating, Lipid-Poor Apolipoprotein A-I. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(3), 421-428. [More Information]
• Shepherd, J., Hunninghake, D., Barter, P., McKenney, J., Hutchinson, H. (2004). Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. 2003. Atherosclerosis Supplements, 5(3), 115-123. [More Information]
• Barter, P. (2004). HDL: A Recipe For Longevity. Atherosclerosis Supplements, 5(2), 25-31. [More Information]
• Wadham, C., Albanese, N., Roberts, J., Wang, L., Bagley, C., Gamble, J., Rye, K., Barter, P., Vadas, M., Xia, P. (2004). High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory Activity. Circulation, 109(17), 2116-2122. [More Information]
• Hime, N., Drew, K., Barter, P., Rye, K. (2004). In Vivo Formation of High-Density Lipoproteins Containing Both Apolipoprotein A-I and Apolipoprotein A-II in the Rabbit. Arteriosclerosis, Thrombosis, and Vascular Biology, 24(5), E-104.
• Barter, P. (2004). Is High-Density Lipoprotein The Protector Of The Cardiovascular System? European Heart Journal Supplements, 6(Supplement A), A19-A22. [More Information]
• Barter, P. (2004). Metabolic Abnormalities: High-Density Lipoproteins. Endocrinology and Metabolism Clinics of North America, 33(2), 393-403. [More Information]
• Tso, C., Barter, P. (2004). Recruitment of endothelial progenitor cells into lipopolysaccharide-stimulated mouse aortic endothelium. Circulation, 110, 151.
• Keech, A., Best, J., Scott, R., Barter, P., Simes, R., Forder, P., Taskinen, M., FIELD study investigators, F. (2004). Significant lipid changes in a large-scale trial of fenofibrate to prevent cardiovascular disease in type 2 diabetes. Journal of the American College of Cardiology, 43(5), A462-A462.
• Barter, P., Best, J., Coleman, P., D'Emden, M., Davis, T., Drury, P., Ehnholm, C., Keech, A., Simes, R., et al (2004). The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular Diabetology, 3(December), 9 - 1-9 - 11. [More Information]

2003

• Rye, K., Wee, K., Curtiss, L., Bonnet, D., Barter, P. (2003). Apolipoprotein-A-II inhibits high density lipoprotein remodeling and lipid-poor apolipoprotein A-I formation. Journal of Biological Chemistry, 278(25), 22530-22536. [More Information]
• Barter, P., Brewer, H., Chapman, M., Hennekens, C., Rader, D., Tall, A. (2003). Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(2), 160-167. [More Information]
• Duong, M., Psaltis, M., Rader, D., Marchadier, D., Barter, P., Rye, K. (2003). Evidence that hepatic lipase and endothelial lipase have different substrate specificities for high-density lipoprotein phospholipids. Biochemistry, 42(46), 13778-13785. [More Information]

2002

• Rye, K., Duong, M., Psaltis, M., Curtiss, L., Bonnet, D., Stocker, R., Barter, P. (2002). Evidence that phospholipids play a key role in pre-β apoA-I formation and high density lipoprotein remodeling. Biochemistry, 41(41), 12538-12545. [More Information]